The National Cancer Institute (NCI) sponsored a workshop to develop a set of standardized
diagnostic and response criteria for acute myeloid leukemia (AML) clinical trials. The French-…

The discovery and development of novel therapeutic products for the treatment of malignancy
is vitally important to those physicians responsible for the management of cancer patients. …

The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) charged
the Biomarker Task Force to develop recommendations to improve the decisions about …

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma,
is clinically heterogeneous: 40% of patients respond well to current therapy and have …

IN 1988, THE National Cancer Institute-sponsored Working Group (NCI-WC) on chronic
lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials in …

The most common human leukemia is B cell chronic lymphocytic leukemia (CLL), a malignancy
of mature B cells with a characteristic clinical presentation but a variable clinical course. …

… Sequences of H1- and N2-RAS oncogene regions were amplified using previously described
conditions and primers (Vasko V, Ferrand M, Di Cristofaro J, et al: J Clin Endocrinol Metab …

… The high dose of Ara-C was initially defined as 2 g/m 2 /d for patients ≥50 and 3 g/m 2 /d for
… the dose to 2 g/m 2 /d for age <50. The standard dose of Ara-C was 200 mg/m 2 for all ages …

Optimal reexpression of most genes silenced through promoter methylation requires the
sequential application of DNA methyltransferase inhibitors followed by histone deacetylase …

Importance The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with
chronic lymphocytic leukemia (CLL). Reasons for discontinuing therapy with this drug and …